Board of Directors

Paul Harder, Independent Non-Executive Chairman

Paul is an executive who has overseen profitable exits from companies in various industries. The companies that Paul has managed and exited include: the sale of Auto Radiator Sales, Inc. (ARS) to Ford Motor Company in December 1998; the sale of Cliffstar Corp. to Cott Corp for $500 million in cash plus additional milestone payments. During his tenure from March 2007 until the sale in 2010, Cliffstar Corp. tripled its EBITDA. In October 2017, Paul was involved in the sale of Clinical Support Services Inc., to Medicine on Time LLC. Paul earned a BBS and MBA from Canisius College.

Bill Burns, Chief Executive Officer

Bill Burns has served as CEO of Neuroprotexeon since 1st June 2015. He served as the President of Minrad Inc. since 1994, including some years with Piramal Healthcare which acquired Minrad Inc. in 2009. Prior to Minrad Inc., he served as President and CEO of Matrx Medical Inc. from 1988 to 1994. Prior to that, he served 13 years with the British Oxygen Corporation (BOC), now a Linde subsidiary, in progressive management positions including Vice President of Marketing of its Anaquest division. Bill is a two-time recipient of the Industry/University Technology Discovery Award. He earned a BBA at St. Norbert College and an MBA at Marquette University.

Matt Napoletano, Chief Operating Officer

Matt has served as COO of Neuroprotexeon since 1st June 2015. He is an accomplished pharmaceutical executive bringing more than 20 years of marketing experience. Prior to joining NPXe, Matt worked in positions of increasing importance at Insys Therapeutics, Cephalon Inc. (Teva Pharmaceutical), and Berlex Laboratories (Bayer). Matt played a lead role in the commercialisation of multiple products and line extensions in the areas of supportive care, pain management, women’s health, diagnostic imaging and radiopharmaceuticals. Matt holds a Bachelor of Science from Shippensburg University.

Jim McAuliffe, Chief Financial Officer

Jim is a financial leader with a wide range of experience in both the public and private sectors for the past 25 years. Prior to joining NPXE, Jim worked at Gibraltar Industries, Uni-Select USA, Rigidized Metals Corp. and Koike Aronson/Ransome. His professional career began at PriceWaterhouse. Jim has played an integral role in many complex financial transactions including registered public debt offerings, acquisition and divestiture reporting. Jim earned a BS and MBA from the University at Buffalo and a CPA from the state of New York.

Ali Arpacioglu, Non-Executive Director

Ali has worked in the pharmaceutical industry since 1978 when he joined Adeka. He served as the General Manager from 1993 to 2007 and has been the CEO since 2007. Alongside his 40 years of involvement in pharmaceuticals, Ali is also the Vice President for Pharmaceutical Manufacturers Association of Turkey, board member of the Turkish Confederation of Employer Associations, a member of the Turkish Industry and Business Association and Turkish Pharmaceutical Industry Assembly member for The Union of Chambers and Commodity Exchanges of Turkey. Ali holds a Bachelor of Science degree in Chemical Engineering from Yildiz Technical University.

DISCLAIMER – IMPORTANT

ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO WHICH THIS GATEPOST GIVES ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY NEUROPROTEXEON LIMITED (“NPXe”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.
THE MATERIALS TO WHICH THIS GATEPOST GIVE ACCESS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN OR RESIDENT IN (OR ORGANISED OR INCORPORATED UNDER THE LAWS OF) THE UNITED STATES OR U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S (“REGULATION S”) UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)), WHEREVER LOCATED, OR PERSONS RESIDENT OR LOCATED IN AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan, or in any jurisdiction in which such offers or sales are unlawful (the “Excluded Territories”) or to U.S. Persons (as such term is defined in Regulation S), wherever located. Any securities issued in connection with an offering have not been and will not be registered under the Securities Act or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States, Australia, Canada or Japan. Accordingly, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States.
The materials are only addressed to and directed at persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and any amendments thereto including Directive 2010/73/EU to the extent implemented in the relevant EEA member state) and any relevant implementing measure in the relevant member state of the EEA (“Qualified Investors”). In addition, in the United Kingdom, the materials are being distributed only to, and are directed at Qualified Investors (as defined above) who are (a) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (b) high net worth entities, and other persons falling within Article 49(2)(a) to (d) of the Order to whom they may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which these materials relates are available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA other than the United Kingdom, and will only be engaged with such persons.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be released or otherwise forwarded, distributed or sent to U.S. Persons or otherwise in or into the United States, Australia, Canada, Japan, or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them to U.S Persons or otherwise in, into or from the United States, Australia, Canada or Japan.
Confirmation of understanding and acceptance of disclaimer
I warrant that I am not a resident of, or located in, the United States, Australia, Canada or Japan or any other jurisdiction where accessing these materials is unlawful, nor a U.S. Person, and I agree that I will not transmit or otherwise send any materials contained in this website to any U.S Person or any other person in the United States, Australia, Canada, Japan or any other jurisdiction where to do so would breach applicable local law or regulation.
I have read and understood the disclaimer set out above. I understand that it may affect my rights and I agree to be bound by its terms. I confirm that I am permitted to proceed to electronic versions of the materials.
NeuroproteXeon does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.
[I ACCEPT] [DON’T ACCEPT]